Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Terminated Phase 1 Interventional

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

NCT01200004
View directory record Official record
Conditions
Advanced Cancers
Interventions
Azacitidine, Lenalidomide, Grifola Frondosa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 19, 2026, 1:08 PM EDT
Terminated Phase 1 Interventional

MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

NCT03634267
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma, Human Papillomavirus-Related Cervical Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8
Interventions
Internal Radiation Therapy, Magnetic Resonance Imaging
Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

NCT04530487
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide, Fludarabine Phosphate, Lapine T-Lymphocyte Immune Globulin, Melphalan, Mycophenolate Mofetil, Tacrolimus, Thiotepa
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 19, 2026, 1:08 PM EDT
Not yet recruiting Not applicable Interventional

Prospective Study To Assess The Outcomes Of Nitrous Oxide Cryoablation For Treatment Of Duodenal Adenomas In Patients With Hereditary Conditions Such As FAP, HNPCC

NCT07859514
View directory record Official record
Conditions
Prospective Study , Questionaires, Outcomes, Nitrous Oxide, Cryoablation, Duodenal Adenoma, Hereditary Conditions, FAP, HNPCC
Interventions
Esophagogastroduodenoscopy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
20 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

NCT01471067
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions
Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI)
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway

NCT03359811
View directory record Official record
Conditions
Peritoneal Cancer
Interventions
Local Anesthetic Solution, Bupivacaine HCl, Liposomal Bupivacaine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Not applicable Interventional

Resting-State Functional MRI in Glioma Patients Before and After Surgery

NCT03964909
View directory record Official record
Conditions
Brain Mass, Glioma
Interventions
Functional Magnetic Resonance Imaging, Magnetic Resonance Imaging, Resting State Functional Connectivity Magnetic Resonance Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

NCT00038844
View directory record Official record
Conditions
Lymphoma, Leukemia
Interventions
Campath-1 H (Alemtuzumab), Fludarabine, Cyclophosphamide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

NCT03070301
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
LEE011, everolimus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 19, 2026, 1:08 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

NCT05673928
View directory record Official record
Conditions
Metastatic Solid Tumor, Brain Metastases
Interventions
Trastuzumab emtansine, Tucatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

NCT05025800
View directory record Official record
Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
Interventions
CD47 Antagonist ALX148, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Terminated Phase 1 Interventional

Glutamine PET Imaging Colorectal Cancer

NCT03275974
View directory record Official record
Conditions
RAS Wild Type, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Carbon C 11 Glutamine, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography, Blood Draw
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

NCT02529813
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive, Minimal Residual Disease, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Tisagenlecleucel
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Not applicable Interventional Results available

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

NCT00496808
View directory record Official record
Conditions
Ductal Carcinoma In Situ
Interventions
Herceptin (Trastuzumab)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 19, 2026, 1:08 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

NCT00500240
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Insulin Glargine, Insulin Aspart
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

NCT02042989
View directory record Official record
Conditions
Advanced Cancers
Interventions
MLN9708, Vorinostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

NCT01630590
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabozantinib, Androgen Ablation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 19, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

NCT00038649
View directory record Official record
Conditions
Myelogenous Leukemia, Chronic, Chronic Phase
Interventions
Gleevec
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 19, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

NCT02978443
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Mucosal Melanoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 19, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

NCT00893997
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome
Interventions
PR-1 vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

NCT00061620
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Tezacitabine (FMdC)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

Phase I Trial of ZIO-101 in Patients With Solid Tumors

NCT00509782
View directory record Official record
Conditions
Solid Tumors
Interventions
ZIO-101
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 19, 2026, 1:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Chemotherapy-Related Toxicities In Ovarian Cancer Patients

NCT00508378
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Interview, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

NCT00936858
View directory record Official record
Conditions
Thyroid Cancer
Interventions
RAD001
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 19, 2026, 1:08 PM EDT